Trends in Benzodiazepine Prescribing to Adults in the United States

This study describes recent trends in benzodiazepine prescribing to US adults and characterizes patients who receive benzodiazepines and other central nervous system (CNS) depressants. This repeated cross-sectional study analyzed benzodiazepine use by adults (ages ≥18 years) in the 2018-2022 Medical Expenditure Panel Surveys, which are nationally representative surveys of the civilian noninstitutionalized population. We examined sex-adjusted annual trends (2018-2022) in benzodiazepine use by age group (ages 18-35, 36-55, and ≥56 years) and pooled marginal differences by age group in any benzodiazepine use and in benzodiazepine use and other CNS-depressant medications, stratified by sociodemographic and clinical characteristics. The analysis involved 104,231 participants. Between 2018 and 2022, annual benzodiazepine use by US adults decreased from 4.7% to 3.4%. This included a greater decrease for adults ages ≥56 years (7.2% to 4.7%) than for those ages 36-55 years (4.4% to 3.4%) or 18-35 years (2.1% to 1.8%). Approximately 41.6% adults treated with benzodiazepines also received other CNS-depressant medications in the same year including a higher percentage aged 36-55 years (44.6%) or ≥56 years (42.9%) than 18-35 years (30.0%). Most benzodiazepine-treated adults with fair or poor general health (72.0%) or with serious psychological distress (62.9%) also received other CNS-depressant medications. Benzodiazepine treatment decreased among US adults between 2018 and 2022, with a greater decline among adults ≥56 years than those 36-55 or 18-35 years. Prescription of benzodiazepines to adults who also received other CNS depressants was common, especially among adults in fair or poor general health or with serious psychological distress.